These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25437996)

  • 1. Hidradenitis suppurativa after renal transplantation: complete remission after switching from oral cyclosporine to oral tacrolimus.
    Ducroux E; Ocampo MA; Kanitakis J; Morelon E; Jullien D; Faure M; Euvrard S
    J Am Acad Dermatol; 2014 Nov; 71(5):e210-1. PubMed ID: 25437996
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term follow-up after conversion from tacrolimus to cyclosporin in renal transplant patients with new-onset diabetes mellitus after transplantation.
    Batista F; Auyanet I; Torregrosa JV; Oppenheimer F
    Transplant Proc; 2012 Nov; 44(9):2582-4. PubMed ID: 23146461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Outcome of renal transplantation after tacrolimus switch to cyclosporine].
    Mesar I; Basić-Jukić N; Bubić-Filipi L; Kastelan Z; Bacak-Kocman I; Kes P
    Acta Med Croatica; 2011; 65(4):311-4. PubMed ID: 22359902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switching from cyclosporine to tacrolimus leads to improved disease-specific quality of life in patients after kidney transplantation.
    Franke GH; Trampenau C; Reimer J;
    Transplant Proc; 2006 Jun; 38(5):1293-4. PubMed ID: 16797285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resolution of gingival overgrowth following change from cyclosporin to tacrolimus therapy in a renal transplant patient.
    Kennedy DS; Linden GJ
    J Ir Dent Assoc; 2000; 46(1):3-4. PubMed ID: 11323935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the new immunosuppressive agents on the occurrence of malignancies after renal transplantation.
    Marcén R; Galeano C; Fernández-Rodriguez A; Jiménez-Alvaro S; Teruel JL; Rivera M; Burgos FJ; Quereda C
    Transplant Proc; 2010 Oct; 42(8):3055-7. PubMed ID: 20970609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation.
    Yussim A; Shaharabani E; Mor E; Lustig S; Bar-Nathan N; Shmueli D; Sobolev V; Dorfman B; Or H; Shapira Z
    Transplant Proc; 1996 Dec; 28(6):3178-9. PubMed ID: 8962233
    [No Abstract]   [Full Text] [Related]  

  • 8. Rapid resolution of gingival hyperplasia after switching from cyclosporine A to tacrolimus.
    Dodd DA
    J Heart Lung Transplant; 1997 May; 16(5):579. PubMed ID: 9171281
    [No Abstract]   [Full Text] [Related]  

  • 9. Breast fibroadenomas in renal transplant recipients.
    Alkhunaizi AM; Ismail A; Yousif BM
    Transplant Proc; 2004; 36(6):1839-40. PubMed ID: 15350492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus-induced neutropenia in renal transplant recipients.
    De Rycke A; Dierickx D; Kuypers DR
    Clin J Am Soc Nephrol; 2011 Mar; 6(3):690-4. PubMed ID: 21258040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of switch from cyclosporine to tacrolimus for fibroadenomas of the breast in kidney transplantation.
    Iaria G; Pisani F; De Luca L; Sforza D; Manuelli M; Perrone L; Bellini I; Angelico R; Tisone G
    Transplant Proc; 2010 May; 42(4):1169-70. PubMed ID: 20534252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporin-induced flushing in a renal transplant recipient resolving after substitution with tacrolimus.
    Ramsay HM; Harden PN
    Br J Dermatol; 2000 Apr; 142(4):832-3. PubMed ID: 10792253
    [No Abstract]   [Full Text] [Related]  

  • 13. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
    Prasad GV; Nash MM; McFarlane PA; Zaltzman JS
    Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paradoxical hidradenitis suppurativa to biologic agents: a case series and literature review.
    Neves JM; Cunha N; Lencastre A; Cabete J
    Int J Dermatol; 2019 Nov; 58(11):e226-e228. PubMed ID: 31290151
    [No Abstract]   [Full Text] [Related]  

  • 15. Early conversion from cyclosporine to tacrolimus increases renal graft function in chronic allograft nephropathy at BANFF stages I and II.
    Marcard T; Ivens K; Grabensee B; Willers R; Helmchen U; Rump LC; Blume C
    Transpl Int; 2008 Dec; 21(12):1153-62. PubMed ID: 18684111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.
    de Jonge H; de Loor H; Verbeke K; Vanrenterghem Y; Kuypers DR
    Clin Pharmacol Ther; 2011 Sep; 90(3):414-22. PubMed ID: 21753749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion to tacrolimus for the treatment of cyclosporine-associated nephrotoxicity in heart transplant recipients.
    Israni A; Brozena S; Pankewycz O; Grossman R; Bloom R
    Am J Kidney Dis; 2002 Mar; 39(3):E16. PubMed ID: 11877596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine.
    Jardine AG
    Transpl Int; 2005 Apr; 18(4):379-84. PubMed ID: 15773954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recalcitrant severe hidradenitis suppurativa successfully treated with cyclosporine A.
    Bianchi L; Hansel K; Stingeni L
    J Am Acad Dermatol; 2012 Dec; 67(6):e278-9. PubMed ID: 23158638
    [No Abstract]   [Full Text] [Related]  

  • 20. The impact of tacrolimus as rescue therapy in children using a double immunosuppressive regimen after heart transplantation.
    Branco KC; Azeka E; Trindade E; Galas FR; Hajjar LA; Benvenuti L; Riso A; Tanamati C; Penha J; Auler JO; Jatene M
    Transplant Proc; 2012 Oct; 44(8):2483-5. PubMed ID: 23026625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.